The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha

Archives of Medical Science

Volumn 3, Issue 2, 2007, Pages 83-92

  Heusch, Philipp ^a   Skyschally, Andreas ^a   Leineweber, Kirsten ^a   Haude, Michael ^b   Erbel, Raimund ^a   Heusch, Gerd ^a,c  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b Lukaskrankenhaus Neuss ^*  (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adenosine; Coronary microembolization; Infarct size; Ischemic preconditioning; TNF alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; REVIEW; UPREGULATION;

EID: 34547753122     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127-134.
2. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
3. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-708.
4. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418-427.
5. Frink RJ, Rooney PA, Trowbridge JO, Rose JR Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200.
6. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101: 570-580.
7. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000; 36: 22-24.
8. Heusch G, Schulz R, Haude M, Erbel R. Coronary microembolization. J Mol Cell Cardiol 2004; 37: 23-31.
9. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-150.
10. Brener SJ, Topol EJ. Troponin, embolization and restoration of microvascular integrity. Eur Heart J 2000; 21: 1117-1119.
11. Herrmann J, Volbracht L, Haude M, et al. Biochemical markers of ischemic and non-ischemic myocardial damage. (German) Med Klin 2001; 96:144-156.
12. Alpert JS, Thygesen K. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513.
13. Abdelmequid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-1536.
14. Califf RM, Abdelmequid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251.
15. Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. Circulation 2000; 101: 604-610.
16. Herrmann J, Haude M, Lerman A, et al. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 2001; 103: 2339-2345.
17. Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 2003; 92: 728-732.
18. Prati F, Pawlowski T, Gil R, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. Circulation 2003; 107: 2320-2325.
19. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780-2783.
20. Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114: 662-669.
21. Wilson RF, Laxson DD, Lesser JR, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1:807-811.
22. Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med 1994; 330: 523-528.
23. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res Cardiol 2006; 101: 373-382.
24. Safian RD. Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis 2002; 44: 437-448.
25. Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006; 47: 981-986.
26. Ritchie ME. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707-1713.
27. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different patholgies. Circulation 2002; 105: 2019-2023.
28. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 1917-1923.
29. Heusch G, Schulz R, Erbel R. Inflammatory markers in coronary heart disease: coronary vascular versus myocardial origin? Circulation 2003; 108: e4.
30. Böse D, Leineweber K, Konorza T, et al. Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am J Physiol Heart Circ Physiol 2007; 292: H2295-2299.
31. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002; 106: 2180-2183.
32. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-116.
33. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol 2002; 282: H611-H614.
34. Ross J Jr. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation 1991; 83: 1076-1083.
35. Dörge H, Neumann T, Behrends M, et al. Perfusioncontraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol 2000; 279: H2587-H2592.
36. Dörge H, Schulz R, Belosjorow S, et al. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51-62.
37. Skyschally A, Haude M, Dörge H, et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 2004; 109: 2337-2342.
38. Arras M, Strasser R, Mohri M, et al. Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine. Basic Res Cardiol 1998; 93: 97-107.
39. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
40. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998; 274: R577-R595.
41. Thielmann M, Dörge H, Martin C, et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002; 90: 807-813.
42. Hannun YA, Bell RM. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 1989; 243: 500-507.
43. Coroneos E, Martinez M, McKenna S, Kester M. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation. J Biol Chem 1995; 270: 23305-23309.
44. Canton M, Skyschally A, Menabo R, et al. Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J 2006; 27: 875-881.
45. Chandel NS, Trzyna WC, McClintock DS, Schumacker PT. Role of oxidants in NF-kappaB activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol 2000; 165: 1013-1021.
46. Lecour S, Rochette L, Opie L Free radicals trigger TNF alpha-induced cardioprotection. Cardiovasc Res 2005; 65: 239-243.
47. Cailleret M, Amadou A, Andrieu-Abadie N, et al. N-acetyl -cysteine prevents the deleterious effect of tumor necrosis factor-alpha on calcium transients and contraction in adult rat cardiomyocytes. Circulation 2004; 109: 406-411.
48. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z. Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J Biol Chem 2004; 279: 13289-13292.
49. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
50. Bolli R. The late phase of preconditioning. Circ Res 2000; 87: 972-983.
51. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 2001; 52:181-198.
52. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-1151.
53. Yellon DM, Dana A. The preconditioning phenomenon: A tool for the scientist or a clinical reality? Circ Res 2000; 87: 543-550.
54. Heusch G. Nitroglycerin and delayed preconditioning in humans, yet another new mechanism for an old drug? Circulation 2001; 103: 2876-2878.
55. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 1990; 82: 2044-2051.
56. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-705.
57. Billinger M, Fleisch M, Eberli FR, Garachemani A, Meier B, Seiler C. Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol 1999; 33:1027-1035.
58. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999; 99: 2085-2089.
59. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276-277.
60. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997; 77: 314-318.
61. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning in human myocardium with adenosine during coronary angioplasty. Circulation 1997; 95: 2500-2507.
62. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Effect of adjunctive intracoronary adenosine on myocardial ischemia, hemodynamic function and left ventricular performance during percutaneous transluminal coronary angioplasty: clinical access to ischemic preconditioning? Coron Art Dis 2000; 11: 421-428.
63. Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 34: 639-650.
64. Tomai F, Crea F, Gaspardone A, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999; 33: 1863-1869.
65. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation 2000; 102: 1216-1220.
66. Birincioglu M, Yang XM, Critz SD, Cohen MV, Downey JM. S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning. Am J Physiol 1999; 277: H2435-H2441.
67. Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetetive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol 1992; 20: 578-586.
68. Hirai T, Fujita M, Yoshida N, Yamanishi K, Inoko M, Miwa K. Importance of ischemic preconditioning and collateral circulation for left ventricular functional recovery in patients with successful intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1993; 126: 827-831.
69. Seiler C, Fleisch M, Garachemani A, Meier B. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol 1998; 32: 1272-1279.
70. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995; 91: 37-47.
71. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995; 91: 291-297.
72. Nakagawa Y, Ito H, Kitakaze M, et al. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". J Am Coll Cardiol 1995; 25: 1076-1083.
73. Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998; 97: 1042-1045.
74. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med 1996; 334: 7-12.
75. Hori M, Inoue M, Kitakaze M, et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol 1986; 250: H509-H518.
76. Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ Res 1985; 56: 651-665.
77. Skyschally A, Schulz R, Gres P, et al. Coronary microembolization does not induce acute preconditioning against infarction in pigs-the role of adenosine. Cardiovasc Res 2004; 63: 313-322.
78. Schulz R, Rose J, Post H, Heusch G. Involvement of endogenous adenosine in ischaemic preconditioning in swine. Pflügers Arch 1995; 430: 273-282.
79. Grund F, Sommerschild HT, Lyberg T, Kirkeboen K, Ilebekk A Microembolization in pigs: effects on coronary blood flow and myocardial ischemic tolerance. Am J Physiol 1999; 277: H533-H542.
80. Saito D, Hasui M, Shiraki T, Kono H. Effects of coronary blood flow, myocardial contractility, and heart rate on cardiac lymph circulation in open-chest dogs. Use of a direct cannulation method for subepicardial lymph vessel. Arzneimittelforschung 1997; 47:119-124.
81. Skyschally A, Gres P, Heusch P, et al. Preinfarction angina: no interference of coronary microembolization with acute ischemic preconditioning. J Mol Cell Cardiol 2005; 39: 355-361.
82. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-518.
83. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNF alpha gene. Cardiovasc Res 2002; 55: 553-560.
84. Ichikawa Y, Miura T, Nakano A, et al. The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioning. Cardiovasc Res 2004; 62: 167-175.
85. Dawn B, Guo Y, Rezazadeh A, et al. Tumor necrosis factor-a does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 2004; 37: 51-61.
86. Yamashita N, Hoshida S, Otsu K, Taniguchi N, Kuzuya T, Hori M. The involvement of cytokines in the second window of ischaemic preconditioning. Br J Pharmacol 2000; 131: 415-422.
87. Skyschally A, Gres P, Hoffmann S, et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007; 100: 140-146.